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Abstract: 
To investigate the clinicopathological characteristics and survival of squamous cell carcinoma and adenocarcinoma 
the cervix using Surveillance, Epidemiology, and End Results database. Patients with a diagnosis of squamous cell 
carcinoma and adenocarcinoma of the cervix were included between 2014 and 2019. Kaplan-Meier method and 
Cox regression models were used. A total of 189 patients were included. Of the patients with known International 
Federation of Gynecology and Obstetrics stage and tumor grade, the stage III disease was diagnosed in 42.78% 
patients, and 26.46.5% patients had poorly or undifferentiated histology and well differentiated are 67.72%. The 5-
year cause specific survival and overall survival were 33.0% and 29.4%, respectively. In multivariate analysis, 
increasing age, advanced stage, and treatment by primary radiotherapy were associated with worse survival 
outcomes. Squamous cell carcinoma and adenocarcinoma of the cervix are rare diseases with aggressive 
characteristics and prone to metastasize and is dismal in prognosis. Reduced survival was associated with 
increasing age, advanced stage, and treatment by primary radiotherapy [1] [3]. 
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AIMS AND OBJECTIVE:  
The aim of this research work is to examine the 
diagnosis and treatment of Analysis of 
clinicopathological features and prognostic factors of 
IA-IIBstage cervical cancer. Cervical cancer that is 
detected early is more likely to be treated 
successfully. Most guidelines suggest that women 
begin screening for cervical cancer and precancerous 
changes at age 21. If cervical cancer is suspected, 
your doctor is likely to start with a thorough 
examination of your cervix. A special magnifying 
instrument (colposcope) is used to check for 
abnormal cells.  
INTRODUCTION:  
Cervical cancer is a cancer arising from the cervix. It 
is due to the abnormal growth of cells that have the 
ability to invade or spread to other parts of the body. 
Early on, typically no symptoms are seen. Later 
symptoms may include abnormal vaginal bleeding, 
pelvic pain, or pain during sexual intercourse. About 
90% of cervical cancer patients are squamous cell 
carcinoma. Adenocarcinoma of the cervix is a rare 
disease accounting for approximately 1-2% of uterine 
cervix malignancies [3]. 
 
Cervical malignant growth is a standout amongst the 
most well-known tumors in ladies around the world. 
Notwithstanding overall endeavors at screening with 
the point of identifying cervical disease in the 
beginning period, numerous malignant growths are 
not found until effectively progressed. Customarily, 
radical hysterectomy or radiation treatment alone has 
been acknowledged as standard treatment for 
beginning time obtrusive cervical malignancy, and 
privately propelled disease has been treated by 
radiotherapy alone comprising of a mix of high-
portion rate intracavitary brachytherapy (ICBT) and 
outside bar radiotherapy (EBRT) (Coia et al, 1990; 
Komaki et al, 1995; Barillot et al, 1997). In the 
previous couple of years, significant advances in the 
administration of privately progressed cervical 
disease have been accounted for. Five randomized 
preliminaries demonstrated improved survival and 
nearby control when cisplatin-based chemotherapy 
was added simultaneously to radiation treatment in 
patients with privately progressed cervical disease 
(Keys et al, 1999; Morris et al, 1999; Rose et al, 
1999; Whitney et al, 1999; Peters et al, 2000). This 
joined methodology approach delivered a flat out 
increment in 5-year survival of 12% as contrasted 
and radiation treatment alone and brought about an 
unexpected change in the standard of consideration 
for this malady. Presently that simultaneous treatment 
with cisplatin-based chemotherapy and radiotherapy 
is the standard treatment for privately progressed 
cervical malignant growth, the fundamental issue in 
treatment is the means by which chemotherapy is 
utilized, very little consideration is given to the 
radiotherapy strategy [5] [6]. 
Invasive cervical cancer (ICC) ranks third as the most 
common malignancy and fourth as the cause of 
cancer-related deaths among women 
worldwide.Despite population-based screening and 
development of advanced medical treatments, the 
morbidity of ICC is still common in developing 
countries like China, yielding 132,300 new cases 
each year. 
Currently, adenocarcinoma (ADC) receives the same 
standard treatments as squamous cell carcinoma 
(SCC): radical hysterectomy, radical hysterectomy 
followed by adjuvant radiotherapy (RT) or primary 
RT for early-stage carcinoma. Concurrent 
chemoradiotherapy (CCRT), which is recommended 
in cases of locally advanced cancer and for patients 
with FIGO early-stage disease, has been widely 
accepted and produces equivalent results. However, 
disparate prognoses have been observed in both SCC 
and ADC patients with the same stage based on 
FIGO guidelines.Moreover, an upward trending 
incidence of ADC has been reported in many 
countries. This upward trend is particularly evident 
among women under age 40.The proportion of ADC 
has doubled over the past decade and accounts for 
approximately 25% of all cases of cervical 
cancer. The poorer prognosis of ADC patients 
compared to those with SCC raises the question of 
whether the current standard treatment for patients 
with SCC is suitable for those with ADCThus, it is of 
great importance to determine the prognostic 
factors involved in ADC so as to establish a 
framework for new therapeutic strategies. 
In the literature, the prognostic significance of some 
clinicopathological factors still remains controversial. 
The aim of the present retrospective study was to 
clarify the clinicopathological factors for predicting 
the prognosis for ADC and squamous cell carcinoma. 
MATERIAL & METHODS:  
All consecutive patients diagnosed with the FIGO 
staging of squamous cell carcinoma and ADC of the 
uterine cervix and treated at The First 
AffiliatedHospital of Xinjiang Medical University, 
China between October 2014 and January 2019 were 
eligible for this study retrospectively. A sum of 100 
new patients with essential intrusive cervical 
carcinoma were treated by radiotherapy, 
chemotherapy and radiography at the First affiliated 
hospital of   Xinjiang Medical University, China. Of 
these patients, 99.0 % had unadulterated squamous 
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cell carcinoma (SCC). The remaining 1 % patient 
with adenocarcinoma were rejected from this 
examination. After an underlying clinical 
examination, all patients experienced a total 
arranging workup, including a total blood tally, blood 
science tests, chest radiography, and biopsy of the 
cervical tumor. Cystoscopy and dribble implantation 
pyelography were performed in all patients; just in 
suspicious case was sigmoidoscopy performed [2] 
[6].  
The quantities of patients are appeared by 
malignancy arranges in Table 1. Stages were resolved 
by the International Federation of Gynecology and 
Obstetrics criteria. Patients with removed metastasis 
(ie organize IVb cervical carcinoma) before treatment 
and patients treated by chemotherapy before radiation 
were prohibited. 
 
Sr. 
No 
Clinical 
Stage 
No. of patients % of patients 
1. Stage IB 09 9 % 
2. Stage IIA 44 44 % 
3. Stage IIB 33 33 % 
4 Stage IIIA 05 5 % 
5. Stage IIIB 07 7 % 
6. Stage IVA 02 2 % 
 Total 100 100 % 
Table 1: Numbers of Patient by cancer staging. 
Patient: 
Data were obtained from the First Affiliated Hospital 
of Xinjiang Medical University, China between 
October 2014 and January 2019 that is maintained by 
the National Cancer Institute and consists of 18 
population-based cancer registries. We included 
squamous cell carcinomapatients from 2014 to 2019 
and permission to access research data files was 
obtained.  
Statistical Analysis: 
Factual examinations were performed with the SPSS 
16.0 programming bundle (IBM, Armonk, NY). 
Synopsis insights are displayed as frequencies and 
rates. The randomization of medical clinic records 
was performed through the probabilistic examining 
process with substitution, and a test for 
straightforward irregular examples was utilized. The 
example comprised of CC patients who were 
conceded somewhere in the range of 2014 and 2019 
and whose restorative records included 
histopathological or anatomopathological 
examinations. Deficient records or cases in which 
treatment was deserted before the consummation of 
the five-year follow-up time were barred. The season 
of survival was determined as the interim between 
the date of conclusion (by biopsy or medical 
procedure) in the emergency clinic record and the 
date of death or the finish of development. The most 
extreme follow-up time was five years; the instance 
of any patient who stayed alive after this point was 
shut. 
Overall survival (OS) and relapse-free survival (RFS) 
were obtained by the Kaplan–Meier method for 
different groups. The Kaplan–Meier estimator, also 
known as the product limit estimator, is a non-
parametric statistic used to estimate 
the survival function from lifetime data. In our 
research, it is often used to measure the fraction of 
patients living for a certain amount of time after 
treatment. The log-rank test was used to compare 
survival curves. Variables that showed a significant 
association with survival were included in 
multivariate analysis based on the Cox proportional–
hazard model. Sites of recurrence were classified as 
local if detected in the pelvis or vagina, and distant if 
detected in extrapelvic locations.  
RESULT:  
Patient numbers by cancer stage of the study are 
shown in Table 1. Mean age of the patients was 46 
years (range, 18–85 years). Of the total 100 patients, 
the numbers of patients with stage Ib, II, and III/ IVA 
disease were 09, 77, and 14 respectively. 
Disease-specific survival curves are shown according 
to cancer stages in Figure 1. The cumulative 5-year 
survival rates for stages Ib, II, and III/IVa disease 
were 93.5, 77.0, and 60.3%, respectively. [10] 
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Figure 1: Disease-specific survival curves for five years and ten years. 
Percentage of prevalence as per the age 
distribution:  
Percentage rates are a useful tool for comparing 
various characters among various populations 
suffering from various diseases having different 
consequences.  Here a detailed description has been 
given of the patients along with their age distribution 
as well as the percentage of prevalence of the 
diseases in various age group.   
 
Different age parameters  Percentage of Prevalence in 
decades of life (%) 
Age (Year)  
Median Range  46  
18-30 18 % 
31-40 9.52 % 
41-50 15.34% 
51-60 22.22% 
61-70 18% 
71-80 10.58% 
80+ Above 6.34% 
Table 2: Percentage of prevalence as per the age distribution 
Differentiation of Cervical Cancer (CC) based on 
different stage of CC: 
Patients were divided into different groups depending 
upon the different stages of cervical cancer they are 
going through in order to treat them in better way. 
They were divided in various groups like well 
differentiated CC, moderately differentiated and 
poorly differentiated respectively. Their detailed 
percentage occurrence is given below; 
 
Well differentiated CC 67.72  % 
Moderately differentiated 
CC 
5.82 % 
Poorly/undifferentiated CC 26.46 % 
 TOTAL 100 % 
Table 3: Differentiation of Cervical Cancer (CC) based on different stage of Lesions. 
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Tumor Size (T): 
The letter "T" plus a number (0 to 4) describes the 
size and location of the tumor, including how much 
the tumor has grown into nearby tissues. Tumor size 
is measured in centimeters (cm). A centimeter is 
roughly equal to the width of a standard pen or 
pencil. A larger tumor or a tumor that has grown 
more deeply into the surrounding tissue receives a 
higher number [9]. The details are given below; 
 
  size (cm)  Parameters 3.9 (0.1-7.4) 
≤4 cm 74.07 % 
>4 cm 25.93 % 
Table 4: Tumor size distribution. 
Different Treatment options in patients of certain 
groups: 
Most squamous cell carcinoma cases are found and 
treated at an early stage, when they can be removed 
or destroyed with local treatment methods. Small 
squamous cell cancers can usually be cured with 
these treatments. Larger squamous cell cancers are 
harder to treat, and fast-growing cancers have a 
higher risk of coming back. In rare cases, squamous 
cell cancers can spread to lymph nodes or distant 
parts of the body. If this happens, treatments such as 
radiation therapy and/or chemotherapy may be 
needed [7] [8]. The percentage of various 
patients’treatment with different techniques is given 
in the table below; 
 
Hysterectomy ± radiotherapy 43.92 
Radiotherapy 16.93 
Give up 6.35 
Radiotherapy  + chemotherapy 14.81 
Surgical option  17.99 
Table 5: Different Treatment options in patients of certain groups. 
Lymphadenectomy: 
No 103 (54.50) 
Yes 86 (45.50) 
Lymph Nodes –ve 97 (51.32) 
Lymph Nodes +ve  92(48.68) 
  
 
*Lymphadenectomy has no significant effects on survival outcome in patients received. 
DISCUSSION: 
Most of the knowledge gained during this research 
study was from the single-institution reports with a 
limited numbers of patients. Here, we identified some 
patients of histologically confirmed squamous cell 
carcinoma between different ages from the Hospitals 
registry. Previous studies have showed that squamous 
cell carcinomaaccounts cervix cancers. The incidence 
rate in our study was 0.7%, which is lower than 
previously reported. About 26.4% of squamous cell 
carcinoma patients have poorly or undifferentiated 
histology. Therefore, it is important to distinguish 
SCCC from poorly differentiated cervical cancer. 
In this we can see that there are many patients who 
are suffering from cervical cancer and they get 
medical treatment according to their stages some 
patients are suffer from 1st stage of cervical cancer 
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and some are suffer from more than first stages they 
all get surgery according to their conditions and then 
some patients get chemotherapy if we see according 
to ages so we have some sample of ages between 18 
to 85 age. Most of the patients consisting of 44 
percent of the patients were suffering with the Stage 
IIA clinical stage followed by stage IIB with 33% 
patients. The patients were treated using various 
treatment options depending on their complications. 
Most of the patients around 44 % patients had gone 
through Radiotherapy along with the Hysterectomy 
for the recovery [12] [14].  
In mostly patients the clinical symptoms are 
abnormal vaginal bleeding or a few of them with 
vaginal discharge and they get radiotherapy and 
chemotherapy as treatment in our data mostly patient 
cancer type is Squamous cell carcinoma with 
abnormal vaginal bleeding symptoms and after these 
patient there are some patient who are suffer from 
Papillary Squamous cell carcinoma caner type and 
they get treatment as surgery with chemotherapy and 
there clinical symptoms are contact bleeding some 
patients are suffering from pelvic lymph node and 
they also get treatment radiotherapy with 
chemotherapy. 
According to our data the mostly patient who are 
suffering this cancer is falling in between 50 to 60 
ages so they get treatment according to their clinical 
symptoms with different stages 1A 11A 1B 11B and 
IA1 phase 1 and phase 11 [13]. 
CONCLUSION & RECOMMENDATION: 
In conclusion, squamous cell carcinoma is a rare 
disease with aggressive characteristics and prone to 
metastasize and is dismal in prognosis. During this 
study this has been concluded that more than 95 % of 
the cervix patients were suffering with the squamous 
cell carcinoma and were treated using various 
techniques. Most of the patients around 44 % patients 
were treated with Hysterectomy & 
radiotherapy.Reduced survival was associated with 
increasing age, advanced stage, and treatment by 
primary radiotherapy. More studies are needed to 
confirm our results and develop optimal management 
of squamous cell carcinoma.  
There are several recommendations of this study. The 
first is the inherent biases existing in any 
retrospective study. However, the major strength of 
the present study is the ability to describe the 
epidemiology, clinicopathological features, treatment 
trends, and survival outcomes of this rare disease 
using a population-based study. Second, Hospital 
database was with lack of information about 
centralized pathologic review, pathological factors 
(margin status and parametrical invasion details of 
radiation therapy and chemotherapy, and the data of 
local and distant recurrence. In addition, there is little 
information available to guide the choice of treatment 
in certain patients.  
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